Re: Kindlings analysis of AFU
"In-situ grade: Average – 2.5%; -REO Conc grade: Poor – 5%; -Deposit size: Medium – 1.2mt, similar to Lynas;
-Capex: High $1.4b+".
WOW that seems an extraordinary capex to get a concentrate uplift to just 5% compared to a grade of 2.5%. Hardly worth bothering??? I note GGG has a lower in situ grade around 1.1% but the concentrate outcome (albeit ONLY a pilot)is now 15%; and the GGG resource size is 11 mt SO FAR for GGG - potential to be multiple of this (compared to 1.2mt for AFU) .....
Summary:
GGG ARU
IN SITU GRADE 1.08% 2.6%
CONC GRADE 15% 5%
REO prod p.a. 52k 20k
DEPOSIT SIZE 10.7mt 1.2mt
CAPEX $1.3b $1.4b
GGG does have sovereign (environmental) risk aplenty, but it stacks up well! I can't help thinking that if the ore REALLY runs under the entire Kvanevjeld Complex as hypothesised then GGG has a "lifetime supply" of rare earths....
There is a comparison of RE players in AFU AGM presso (page 21) at http://www.asx.com.au/asxpdf/20121130/pdf/42bmj2djxdtcg6.pdf which is interesating.
Keep up the analysis Kindling!!
- Forums
- ASX - By Stock
- ETM
- ree projects
ree projects, page-4
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ETM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.58M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.0¢ | $19.58K | 966.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 775714 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 139369 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 775714 | 0.020 |
3 | 1370000 | 0.019 |
2 | 946590 | 0.018 |
1 | 1078254 | 0.017 |
2 | 1480386 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 139369 | 1 |
0.022 | 829344 | 1 |
0.024 | 400000 | 1 |
0.025 | 600000 | 2 |
0.026 | 15000 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
ETM (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online